An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (The "ACT IV" Study)
To confirm that the addition of rindopepimut/GM-CSF to adjuvant temozolomide improves overall survival in patients with newly diagnosed EGFRvIII positive glioblastoma who have undergone gross-total resection.
Neuroscience - Brain Tumor,
Tara Benkers, MD
- Patients with histologically confirmed, newly diagnosed, de novo glioblastoma.
- Surgical resection followed by conventional chemoradiation with temozolomide attempted.
- No history, presence, or suspicion of metastatic disease.
- No additional treatment for glioblastoma, aside from surgical resection and chemoradiation with temozolomide.
Nathan Hansen and Becky Wood